

Corneal Transplant Follow-up Study - impact of tissue matching

Submission date
23/09/2008

Recruitment status
No longer recruiting

☐ Prospectively registered

☐ Protocol

Registration date
06/10/2008

Overall study status
Completed

☐ Statistical analysis plan

☒ Results

Last Edited
27/07/2020

Condition category
Injury, Occupational Diseases, Poisoning

☐ Individual participant data

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Prof John Armitage

Contact details
Bristol Eye Hospital
Lower maudlin Street
Bristol
United Kingdom
BS1 2LX
+44 117 34 24585
w.j.armitage@bristol.ac.uk

Additional identifiers

Protocol serial number
N/A

Study information

Scientific Title
Evaluation of HLA class II histocompatibility matching and cytokine polymorphisms in corneal transplantation

Acronym

CTFS II

Study objectives

Primary hypothesis:

HLA class II tissue matching between donors and recipients decreases the risk of cell-mediated rejection in high risk corneal transplants.

Secondary hypothesis:

Cytokine polymorphisms modulate the cell-mediated rejection response in high risk corneal transplants.

Ethics approval required

Old ethics approval format

Ethics approval(s)

South West Research Ethics Committee:

Original study approved on 11/12/1997 (ref: MREC/97/6/8)

Study extension approved on 13/9/2001 (ref: MREC/01/6/77)

Study design

Multicentre, prospective, longitudinal study using cohort minimisation for patient allocation

Primary study design

Interventional

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Corneal transplantation

Interventions

Patients receive a corneal transplant from a donor matched for HLA class I antigens (not more than two HLA-A and/or HLA-B mismatches combined) with 0, 1 or 2 HLA class II (HLA-DR) mismatches. The level of HLA-DR mismatching defines the study group and is allocated by cohort minimisation. Data are submitted at the time of surgery and the patients are followed up at 6 months, 1, 2, 3, 4 and 5 years postoperatively. Follow-up data include whether the graft has failed, occurrence of rejection episodes, postoperative interventions and medication (including topical steroids and systemic immunosuppressives).

Intervention Type

Other

Phase

Not Specified

Primary outcome(s)

Time to first rejection

Key secondary outcome(s)

Time to graft failure

Completion date

31/12/2014

Eligibility

Key inclusion criteria

Patients of any age or sex tissue typed by polymerase chain reaction using sequence-specific primers (PCR-SSP) or PCR using sequence-specific oligonucleotides (PCR-SSO) with corneal disease requiring a corneal transplant and with the following conditions that increase the risk of cell-mediated rejection:

1. Previously failed corneal transplant
2. Vascularised cornea
3. Ocular inflammatory disease
4. Bullous keratopathy consequent to previous ocular surgery

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Other

Sex

All

Total final enrolment

1077

Key exclusion criteria

Patients requiring corneal transplants where the risk of rejection is low (e.g., keratoconus and Fuchs' endothelial dystrophy) and where there are no known pre-operative risk factors for rejection.

Date of first enrolment

01/09/1998

Date of final enrolment

31/12/2014

Locations

Countries of recruitment

United Kingdom

England

Study participating centre
Bristol Eye Hospital
Bristol
United Kingdom
BS1 2LX

Sponsor information

Organisation
University of Bristol (UK)

ROR
<https://ror.org/0524sp257>

Funder(s)

Funder type
Charity

Funder Name
Start-up funding: NHS Executive South & West R&D (UK) (ref: R/14/9.96)

Funder Name
Subsequent funding: National Eye Research Centre (UK) (ref: SCIAD036)

Results and Publications

Individual participant data (IPD) sharing plan

The data collected for this trial are stored and maintained by NHS Blood and Transplant (NHSBT) in the UK Transplant Registry (UKTR). Corneal transplants in the UK are routinely followed for 5 years by NHSBT and this mechanism was used for the capture of follow-up data for the CTFS II transplants at the following time points: time of transplant, then postoperatively at 6, 12, 24, 36, 48 and 60 months. The UKTR contains patient identifiable data (compliant with GDPR) and is not therefore publicly available.

IPD sharing plan summary
Stored in repository

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Basic results		27/07/2020	27/07/2020	No	No
Other publications	baseline characteristics	01/01/2019	23/09/2019	Yes	No
Participant information sheet	Participant information sheet	11/11/2025	11/11/2025	No	Yes